Literature DB >> 17016580

Preferentially enhanced gene expression from a synthetic human telomerase reverse transcriptase promoter in human cancer cells.

Sung Jin Kim1, Han Saem Lee, June Ho Shin, Chul Geun Kim, Sunjoo Jeong, Keerang Park, Han Choe, Heuiran Lee.   

Abstract

Although the human telomerase reverse transcriptase (hTERT) promoter can regulate cancer-specific genes, it is generally too weak to be effective. We therefore attempted to improve the potency of synthetic hTERT promoters by fusing the core element (E) of the hTERT promoter (H) and the tripartite leader sequence (T) from human adenovirus 5 in a combinatorial manner. To determine the potential as cancer-specific promoters, we measured luciferase activity driven by the chimeric hTERT promoters in human cancer cells. Among various constructs, the E3-H-T promoter induced the strongest luciferase activity in all the tested cancer cells. SK-Hep1 and Hela cells experienced 1000- and 11-fold higher expression than the basic hTERT promoter, respectively. Relative to the SV40 universal promoter, the E3-H-T promoter led to higher levels of gene expression. Using EMSA, we found that the hTERT enhancer region was specifically bound to c-Myc and Sp1. Thus, the data suggest that the E3-H-T promoter with up-regulated cancer-specific gene expression could be useful in cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016580

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Epidermal growth factor activates telomerase activity by direct binding of Ets-2 to hTERT promoter in lung cancer cells.

Authors:  Chung-Ping Hsu; Li-Wen Lee; Sheau-Chung Tang; I-Lun Hsin; Yu-Wen Lin; Jiunn-Liang Ko
Journal:  Tumour Biol       Date:  2015-02-14

2.  Expression of tumor suppressor REIC/Dkk-3 by a newly improved adenovirus vector with insertion of a hTERT promoter at the 3'-side of the transgene.

Authors:  Endy Widya Putranto; Rie Kinoshita; Masami Watanabe; Takuya Sadahira; Hitoshi Murata; Ken-Ichi Yamamoto; Junichiro Futami; Ken Kataoka; Yusuke Inoue; I Made Winarsa Ruma; I Wayan Sumardika; Chen Youyi; Miyoko Kubo; Yoshihiko Sakaguchi; Kenji Saito; Yasutomo Nasu; Hiromi Kumon; Nam-Ho Huh; Masakiyo Sakaguchi
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

3.  Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2.

Authors:  Hye Jin Yun; Young-Hwa Cho; Youngsun Moon; Young Woo Park; Hye-Kyoung Yoon; Yeun-Ju Kim; Sung-Ha Cho; Young-Ill Lee; Bong-Su Kang; Wun-Jae Kim; Keerang Park; Wongi Seo
Journal:  Exp Mol Med       Date:  2008-06-30       Impact factor: 8.718

4.  Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma.

Authors:  Yue-Min Li; San-Tai Song; Ze-Fei Jiang; Qi Zhang; Chang-Qing Su; Guo-Qing Liao; Yi-Mei Qu; Guo-Qing Xie; Ming-Ying Li; Fei-Jiao Ge; Qi-Jun Qian
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

5.  A novel gene expression system strongly enhances the anticancer effects of a REIC/Dkk-3-encoding adenoviral vector.

Authors:  Masami Watanabe; Masakiyo Sakaguchi; Rie Kinoshita; Haruki Kaku; Yuichi Ariyoshi; Hideo Ueki; Ryuta Tanimoto; Shin Ebara; Kazuhiko Ochiai; Junichiro Futami; Shun-Ai Li; Peng Huang; Yasutomo Nasu; Nam-Ho Huh; Hiromi Kumon
Journal:  Oncol Rep       Date:  2013-12-31       Impact factor: 3.906

6.  A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy.

Authors:  Tetsuo Oka; Kazuhiko Kurozumi; Yosuke Shimazu; Tomotsugu Ichikawa; Joji Ishida; Yoshihiro Otani; Toshihiko Shimizu; Yusuke Tomita; Masakiyo Sakaguchi; Masami Watanabe; Yasutomo Nasu; Hiromi Kumon; Isao Date
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.